Orexo announces that Abstral is ready for launch in France.

Orexo announced that ProStrakan Group plc, Orexo's partner for Abstral in Europe and North America, confirms that it has completed the reimbursement pricing process with the French authorities for its pan-European breakthrough cancer pain product, Abstral, earlier than expected and, as a result, plans to launch this product in the important French market in Jul 2009. Abstral is a new formulation of fentanyl, a long-established opioid, used for the management of episodes of breakthrough pain experienced by cancer patients who are already receiving opioid analgesics for their chronic pain. In Jun 2008 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines …